Results 171 to 180 of about 95,123 (282)

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Revisiting the impact of BRCA1 pathogenic variants on the aggressiveness of prostate cancer. [PDF]

JNCI Cancer Spectr
Sasagawa H, Narita S, Matsuda K, Kosaka T, Momozawa Y.   +4 more
europepmc   +1 more source

Reprogramming SREBP1‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention

International Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.
What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan, Elizabeth T. Bartom, Carolina H. Chung, Xingyu Guo, Kyli Berkley, Seyyedmohsen Hosseinibarkooie, Zahra Assadi, Shao Huan Samuel Weng, Raymond Moellering, Oukseub Lee, Ruohui Chen, Wonhwa Cho, Sriram Chandrasekaran, Susan E. Clare, Seema A. Khan   +14 more
wiley   +1 more source

Replication stress-inducing ELF3 upregulation promotes BRCA1-deficient breast tumorigenesis in luminal progenitors. [PDF]

Elife
Zhou J, Zhou XA, Hu L, Ma Y, Zhan J, Xu Z, Zhou M, Shen Q, Liu Z, Ma S, Xie Y, Wang J.   +11 more
europepmc   +1 more source

Long‐term impact of stressful life events on breast cancer risk: A 36‐year genetically informed prospective study in the Finnish Twin Cohort

International Journal of Cancer, Volume 158, Issue 6, Page 1489-1497, 15 March 2026.
What's new? Breast cancer results from a combination of genetic and environmental causes, and the cumulative effect of stressful life events may be a contributing factor. Here, the authors analyzed data from cohort and twin‐pair studies including 36 years of follow‐up to find out how stressful life events affect breast cancer risk. They found that even
Elissar Azzi, Hannes Bode, Teemu Palviainen, Mikaela Hukkanen, Miina Ollikainen, Jaakko Kaprio   +5 more
wiley   +1 more source

Comparative analysis of telomere length in peripheral blood of breast cancer BRCA1 mutation carriers and non-carriers. [PDF]

Discov Oncol
Uttarilli A, Balounova K, Tomasova K, Hanak P, Saskova K, Vodicka P, Vodickova L, Hemminki K, Lubinski J, Kroupa M.   +9 more
europepmc   +1 more source

If treating obesity with GLP‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials

Diabetes, Obesity and Metabolism, EarlyView.
Anastasios Tentolouris, Ioannis Ntanasis‐Stathopoulos   +1 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Identifying a Recurrent BRCA1 Variant in the Qatari Population With Unique Genotype-Phenotype Correlations. [PDF]

Mol Genet Genomic Med
Bujassoum Al-Bader S, Al-Mulla H, Al-Habish H, Kusasi S, Abduo N, Bakheet N, Ghazouani H, Sidenna M, Abbaszadeh F, Alsulaiman R.   +9 more
europepmc   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source